Currently Mylan has 21 facilities and 15,000 employees working in India.

Ogivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the...

Drug firm Mylan NV has launched generic Harvoni tablets, used to treat Hepatitis C, under the brand name 'MyHep LVIR' in India.

Sovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.

Drug major Mylan has rejected a $40 billion unsolicited merger offer from Israel's Teva Pharmaceutical Industries calling the bid undervalu...

US-based company's Indian arm Mylan NV has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the country, i...

Mylan will pay $750 million to buy the women’s health business of Mumbai-based Famy Care and expand its presence in the market for women’s ...

Mylan is said to have pipped private equity bids from Bain Capital and Advent to move closer to a deal. Hong Kong-based AIF Capital holds 1...

The CCI observed that "there is horizontal overlap" between the pharmaceutical products of Mylan and Abbott in India with respect to certai...

Bangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...

Drug major Mylan Inc today said it has launched breast cancer drug Hertraz Herceptin in India.

Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan.

Biocon said it has received approval to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer.

It observed that the proposed acquisition by Mylan was with the intent to export products to be manufactured at the said facility.

Matrix Labs’ CEO Rajiv Malik, who came on board July last year, appears to have his task cut out.

The $1.2-bn US-based Mylan Labs may just have captured value across the chain with the Matrix deal.

The generic drugs major will acquir Hyderabad-based Matix Lab in a cash-and-stock deal worth Rs 3,424 cr.